For more than 25 years, Burkhard Schlütermann has been responsible in senior and management positions for technical R&D operations within pharmaceutical and analytical development organizations. He has been successful in obtaining marketing approvals of numerous prescription and OTC preparations designed as immediate and modified release drug products. In his previous position, he has overseen Aenova’s operational pharmaceutical and analytical development activities as Vice President R&D since 2011. Burkhard held the position as CSO in the research and development organization of Advanced Drug Delivery (ADD) Technologies, Switzerland, and project leader and project team representative positions at Novartis/Ciba-Geigy in Switzerland and the US. His experience also includes the establishment of a network of CROs, as well as organizing and take-over of sponsor responsibility for various pharmacokinetic studies.
Burkhard graduated as pharmacist from the University of Münster and as PhD in Pharmaceutical Sciences from the University of Munich. He is the inventor of several patents on particle engineered APIs, oral dosage forms and associated manufacturing techniques.